Cardiovascular Disease, Interleukin-6, and Risk of Mortality in Older Women: The Women’s Health and Aging Study

Background —Systemic chronic inflammation has been found to be related to all-cause mortality risk in older persons. We investigated whether specific chronic conditions, particularly cardiovascular disease (CVD), affect the association between high interleukin (IL)-6 level and mortality in a sample of disabled older women. Methods and Results —IL-6 serum level was measured at baseline in 620 women ≥65 years old. The presence and severity of medical conditions was ascertained by standard criteria that used multiple sources of information. The sample was surveyed over the 3-year follow-up. After adjustment for potential confounders, compared with those in the lowest tertile, women in the highest IL-6 tertile were at higher risk of all-cause mortality. The presence of CVD, however, strongly affected the risk of mortality associated with high IL-6. Among women with prevalent CVD, those with high IL-6 levels had >4-fold risk of death (RR 4.6; 95% CI 2.0 to 10.5) compared with women in the lowest tertile, whereas the relative risk associated with high IL-6 among those without CVD was much lower and not significant (RR 1.8; 95% CI 0.7 to 4.2). Adjustment for all chronic diseases and disease severity measures, including ankle-brachial index, forced expiratory volume, and exercise tolerance, did not change the results. Conclusions —IL-6 level is helpful in identifying a subgroup of older CVD patients with high risk of death over a period of 3 years. Systemic inflammation, as measured by IL-6, may be related to the clinical evolution of older patients with CVD.

[1]  R. Westendorp,et al.  C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[2]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[3]  L. Bouter,et al.  von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[4]  A. Rebuzzi,et al.  Enhanced inflammatory response in patients with preinfarction unstable angina. , 1999, Journal of the American College of Cardiology.

[5]  ChristodoulosStefanadis,et al.  Increased Proinflammatory Cytokines in Patients With Chronic Stable Angina and Their Reduction By Aspirin , 1999 .

[6]  P. Nihoyannopoulos,et al.  Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. , 1999, Circulation.

[7]  S. Kaul,et al.  Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. , 1999, Circulation.

[8]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[9]  H. Cohen,et al.  Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. , 1999, The American journal of medicine.

[10]  A. Rebuzzi,et al.  Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. , 1999, Circulation.

[11]  S. Frøland,et al.  Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. , 1999, The American journal of cardiology.

[12]  H. Miller,et al.  Role of cytokines in heart failure. , 1998, American heart journal.

[13]  D. Fukai,et al.  Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. , 1998, Journal of the American College of Cardiology.

[14]  D. Papanicolaou,et al.  The Pathophysiologic Roles of Interleukin-6 in Human Disease , 1998, Annals of Internal Medicine.

[15]  L. Kuller,et al.  Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[16]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[17]  L. Kuller,et al.  Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. , 1996, American journal of epidemiology.

[18]  G. Ciliberto,et al.  Elevated levels of interleukin-6 in unstable angina. , 1996, Circulation.

[19]  Linda P. Fried,et al.  The Women's Health and Aging Study: Health and Social Characteristics of Older Women with Disability , 1995 .

[20]  Wen H. Sun,et al.  The Role of Interleukin-6 in Certain Age-Related Diseases , 1994, Drugs & aging.

[21]  A. Rebuzzi,et al.  The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.

[22]  A. Becker,et al.  Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. , 1994, Circulation.

[23]  J. Polak,et al.  Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. , 1993, Circulation.

[24]  Harry,et al.  C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. , 1993, Blood.

[25]  Simon C Watkins,et al.  Negative inotropic effects of cytokines on the heart mediated by nitric oxide. , 1992, Science.

[26]  A. Roche,et al.  Reference data for obesity. , 1991, The American journal of clinical nutrition.

[27]  W. Dietz,et al.  Reference data for obesity: 85th and 95th percentiles of body mass index (wt/ht2) and triceps skinfold thickness. , 1991, The American journal of clinical nutrition.

[28]  H. Fillit,et al.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.

[29]  M. Pepys,et al.  Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. , 1983, Advances in immunology.

[30]  E F Cook,et al.  Comparative Reproducibility and Validity of Systems for Assessing Cardiovascular Functional Class: Advantages of a New Specific Activity Scale , 1981, Circulation.